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Background:  Several  reports  have  identiﬁed  that  decline  in  renal  function  and  presence  of proteinuria
are  closely  associated  with  incidence  of atrial ﬁbrillation  (AF).  However,  it is  still unclear  whether  these
kidney-related  markers  are  associated  with  the progression  of  AF from  paroxysmal  to  persistent  form.
Methods  and results:  Among  the  new  patients  who  visited  the Cardiovascular  Institute  Hospital
between  2004  and  2010  (Shinken  Database  2004–2010,  n  =  15,227),  both  estimated  glomerular  ﬁl-
tration  rate  (eGFR)  and  proteinuria  were  measured  in  1074  AF  patients  (paroxysmal/persistent
579/495, respectively),  who  were  divided  into  tertiles  of  eGFR  (the  borderlines  were  60.07
and  73.67  ml [min−1]  1.73  [m−2], respectively),  and  then  further  divided  into  the two  categories
with/without  proteinuria.  The  average  value  of  eGFR  was  lower  (63.1  ml  [min−1] 1.73  [m−2]  vs.
68.8  ml [min−1] 1.73 [m−2], p <  0.001)  and  the  detection  rate  of proteinuria  was  higher  (13.7%  vs. 8.5%,
p  = 0.006)  in  patients  with  persistent  AF  than  in  those  with  paroxysmal  AF,  respectively.  In the  multivari-
ate  analysis  without  parameters  of echocardiography  [left  ventricular  ejection  fraction  (LVEF)  and  left
atrial dimension  (LAD)],  both  eGFR  and proteinuria  were  independently  associated  with  persistent  AF,
but  the  association  was  abolished  when  the  model  included  LAD  and  LVEF.
Conclusions:  In  the present  analysis  with  cross-sectional  design,  both  eGFR  and  proteinuria  were  appar-
ently linked  to the  persistent  form  of  AF, but  their  role  in  the  pathogenesis  does  not seem  to  exceed  the
atrial  stretch  and  remodeling,  represented  by  LAD  and  LVEF.
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As the graying of the societies in developing countries, atrial
brillation (AF) becomes an important medical problem, because
he incidence of this arrhythmia is expected to increase remarkably
n the coming decades [1].  AF is progressive and associated with
ncreased morbidity and mortality, but the evidence with longi-
udinal observation of its time course has shown the limitations in
he traditional approach with anti-arrhythmic drugs to suppress AF
rogression [2]. Thus, recent studies seem to have been shifted to a
rend to investigate the risk factors for AF progression more linked
o the pathogenesis of structural and electrical remodeling in left
trium [3,4], which would be a target of the “up-stream” therapy.
∗ Corresponding author at: Department of Cardiology, The Cardiovascular Insti-
ute, 3-2-19 Nishiazabu, Minato-Ku, Tokyo 106-0031, Japan. Tel.: +81 3 3408 2151;
ax: +81 3 3408 2159.
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Recently, several reports have clariﬁed that AF is closely asso-
ciated with the decline in renal function and the presence of
proteinuria, both of which are the representing markers for chronic
kidney disease (CKD) [5–10].  The relationship could be explained
by the concept that both AF and renal dysfunction or proteinuria
are closely associated with various cardiovascular diseases and risk
factors [11–19] and also with pathogenesis related to systemic
inﬂammation [20,21]. Following the concept, these kidney-related
markers should be associated with not only incidence but also
progression of AF from a transient form to a continuous one,
because sustaining of AF is encouraged by ﬁbrosis of atrium
[22], which is closely linked to the enhancement of inﬂamma-
tion [23]. However, to date, previous reports have not addressed
the association between these kidney-related markers and AF
progression.To obtain the basic information regarding this issue, we
investigated the distribution of AF types (proportion of persis-
tent form) in the combined classiﬁcations of renal function and
proteinuria.
vier Ltd. All rights reserved.
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tudy patients
The Shinken Database was established comprising all the new
atients visiting the Cardiovascular Institute Hospital in Tokyo,
apan (“Shinken” is an abbreviated name in Japanese for the name
f the hospital), and excluded patients with active cancer and any
oreign travelers. The principle aim of this hospital-based database
s a surveillance of the prevalence and prognosis of cardiovas-
ular diseases in the urban areas of Japan [24–34].  The registry
tarted in June 2004, and thereafter patients have continually been
egistered to the database annually. The health status and the inci-
ence of cardiovascular events and mortality are maintained in the
atabase by being linked to the medical records of the hospital, and
y mailings sent to the patients approximately once or twice per
ear.
The data in the present study were derived from this database
etween June 2004 and March 2011 (Shinken Database 2004–2010)
hich includes 15,227 new visiting patients. In the database,
oth serum creatinine measurements and proteinuria data were
vailable in 6951 patients, where 1074 patients were diagnosed
ith AF which comprised the study population of the present
tudy.
ata collection
In each patient, after obtaining an electrocardiogram and chest
-ray, the cardiovascular status was evaluated using echocar-
iography, an exercise test, 24-h Holter recordings, and blood
aboratory data within 3 months after the initial visit, according
o the decision by the attending physicians. Details have been pub-
ished elsewhere [24,25].
ssessment of renal function
Serum creatinine was measured in samples collected within
 months after the initial visit. Estimated glomerular ﬁltration rate
eGFR) was calculated using the revised equations for Japanese
eGFR = 194 × SCr−1.004 × Age−0.287 × 0.739 [if female]) [35]. The
resence of proteinuria was measured by the spot urine test
btained at the initial visit to our hospital. The presence of pro-
einuria was determined when the result of the qualitative analysis
howed (+) or greater [including (+), (2+) and (3+)].
eﬁnition of AF
In the present study, AF was diagnosed by electrocardiographic
ecordings, including 12-lead surface electrocardiograms (ECG) and
4-h Holter recordings within the 3 months after the initial visit,
nd by the medical history of AF from the referring physicians. New-
nset AF later than 3 months after the initial visit was not included
n the diagnosis of AF in the present study.
Then, AF patients were classiﬁed into paroxysmal or persistent
orm according to the criteria as follows: (1) paroxysmal AF was
etermined when any of ECGs or 24-h Holter recordings showed
inus rhythm during the 3 months after the initial visit, and (2) the
est was determined as persistent AF.
tatistical analysisFor the patient characteristics, data (except percentages) are
resented as mean ± standard deviation. Group comparisons with
onsecutive variables were performed using the Student’s t-test.
roportions of patients were compared using Fisher’s exact test.iology 61 (2013) 53–57
The relations of eGFR and proteinuria to the persistent form of AF
were analyzed by two types of logistic regression models, where the
parameter of eGFR was  either of categorical or consecutive value.
In the model with categorical values of eGFR, the study patients
were divided into tertiles, where the borderlines were 60.07 and
73.67 ml  (min−1) 1.73 (m−2), respectively. First, the relationships of
eGFR (both consecutive and categorical value) and presence of pro-
teinuria with the persistent form of AF were analyzed in univariate
models (Model A). Then the Model A was  adjusted by patient back-
grounds which were signiﬁcantly different between those with
paroxysmal and persistent AF [selecting from age, sex, body mass
index, hypertension, diabetes mellitus, dyslipidemia, heart failure,
organic cardiac disease (valvular heart disease, ischemic heart dis-
ease, and cardiomyopathy) and history of cerebral infarction or
transient ischemic attack; Model B]. Furthermore, we performed
2 types of additional adjustments: (1) Model C, where Model A was
adjusted by covariates in Model B, added by the use of antiarrhyth-
mic  drugs (AADs) which were signiﬁcantly different between those
with paroxysmal and persistent AF (selecting from AADs class 1,
2, 3 and 4, and digitalis), and (2) Model D, where Model A was
adjusted by covariates in Model B, added by echocardiographic
parameters including left ventricular ejection fraction (LVEF) and
left atrial diameter (LAD). The adjustment was performed by the
forward stepwise method.
All analyses were performed using SPSS (SPSS, Inc., Chicago, IL,
USA) for Windows (Microsoft Corp., Redmond, WA,  USA), version
19.0 software. Statistical signiﬁcance was set at p < 0.05.
Ethical issues
The ethical committee at the Cardiovascular Institute granted
ethical permission for this study and all the patients gave written
informed consent.
Results
Characteristics of study patients
The characteristics of the study patients are shown in Table 1.
Among the AF patients (n = 1074), paroxysmal and persistent
forms were 579 (53.9%) and 495 (46.1%), respectively. Average age
(65.5 ± 11.8 years vs. 61.8 ± 12.4 years, p < 0.001) and the preva-
lence of heart failure (33.3% vs. 19.2%, p < 0.001) and organic heart
diseases (46.7% vs. 30.1%, p < 0.001) were signiﬁcantly higher in
patients with persistent form than those with paroxysmal one. Also,
the average value of eGFR was lower (63.1 ml  (min−1) 1.73 (m−2)
vs. 68.8 ml  (min−1) 1.73 (m−2), p < 0.001) and the detection rate of
proteinuria was higher (13.7% vs. 8.5%, p = 0.006) in patients with
persistent AF than in those with paroxysmal, respectively.
The prevalence of persistent form in AF patients according to the
level of eGFR and the presence of proteinuria
Fig. 1 shows the prevalence of persistent form in the cate-
gories of eGFR tertiles separated by the presence of proteinuria. In
patients without proteinuria, the prevalence of persistent AF clearly
increased from 34.0% in the high eGFR tertile to 43.0% and 57.6%
in the middle and the low eGFR tertiles, respectively. Meanwhile,
the prevalence of persistent form was higher in patients with pro-
teinuria compared with those without it, where the prevalence oftertile to 73.3% in the middle one. Unexpectedly, the prevalence
was 57.6% in the low eGFR tertile, which was  lower than that in
the middle tertile and similar to that in the high tertile among the
groups with proteinuria.
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Table  1
Characteristics of atrial ﬁbrillation patients separated by paroxysmal and persistent form: Shinken Database 2004–2010, Tokyo, Japan.
Paroxysmal AF (n = 579) Persistent AF (n = 495) p-Value
Age, years 61.8 ± 12.4 65.5 ± 11.8 <0.001
Male 423 (73.1) 359 (72.5) 0.891
Body  mass index, kg (m−2) 23.7 ± 3.4 23.8 ± 3.6 0.609
Co-existing cardiac diseases
Congestive heart failure 111 (19.2) 165 (33.3) <0.001
Organic cardiac disease 174 (30.1) 231 (46.7) <0.001
Valvular heart disease 89 (15.4) 158 (31.9) <0.001
Ischemic heart disease 61 (10.5) 58 (11.7) 0.559
Myocardial infarction 24 (4.1) 24 (4.8) 0.657
Cardiomyopathy 62 (10.7) 81 (16.4) 0.007
Other conditions
Hypertension 269 (46.5) 239 (48.3) 0.581
Diabetes mellitus 87 (15.0) 112 (22.6) 0.002
Dyslipidemia 184 (31.8) 115 (23.2) 0.002
History of cerebral infarction or TIA 32 (5.5) 46 (9.3) 0.019
Antiarrhythmic drugs
Antiarrhythmic drug class 1 238 (41.1) 49 (9.9) <0.001
Antiarrhythmic drug class 2 212 (36.6) 182 (36.8) 1.000
Antiarrhythmic drug class 3 18 (3.1) 23 (4.6) 0.204
Antiarrhythmic drug class 4 181 (31.3) 77 (15.6) <0.001
Digitalis 53 (9.2) 163 (32.9) <0.001
Echocardiographic parameters
Left ventricular ejection fraction 63.6 ± 11.7 57.3 ± 15.2 <0.001
Left  atrial diameter 38.3 ± 7.7 48.1 ± 9.5 <0.001
Markers for CKD
Estimated GFR, ml  (min−1) 1.73 (m−2) 68.8 ± 16.1 63.1 ± 18.3 <0.001
Proteinuria 49 (8.5) 68 (13.7) 0.006
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he categorical and consecutive data are presented as number (%) and mean ± stan
he relation of eGFR and proteinuria to persistent form in AF
atients
In the non-adjusted logistic regression model, eGFR and pro-
einuria were signiﬁcantly associated with persistent AF, where the
dds ratios of middle and low tertiles of eGFR compared with the
igh tertile were 1.49 (95% CI 1.16–1.91, p = 0.002) and 2.23 (95%
I 1.74–2.85, p < 0.001), respectively, and those of eGFR in consecu-
ive values and proteinuria were 0.98 (0.97–0.99, p < 0.001) and 1.73
1.17–2.56, p = 0.005), respectively (Table 2, Model A). These odds
atios were mostly similar when adjusted by various patient back-
rounds, where the odds ratios of middle and low tertiles of eGFR
ompared to the high tertile were 1.48 (95% CI 1.11–2.06, p = 0.007)
nd 2.11 (95% CI 1.54–2.88, p < 0.001), respectively, and those of
GFR in consecutive values and proteinuria were 0.98 (0.97–0.99,
 < 0.001) and 1.51 (1.03–2.22, p = 0.035), respectively (Table 2,
odel B). However, when the information regarding the use of
ig. 1. Prevalence of persistent atrial ﬁbrillation in combined categories of esti-
ated glomerular ﬁltration rate (GFR) and proteinuria. The number of atrial
brillation patients (persistent/total) in high (T1), middle (T2), and low (T3) ter-
ile of estimated GFR were 113/332, 141/328, and 171/297 in the groups without
roteinuria, and 13/26, 22/30, and 33/61 in the groups with it.merular ﬁltration rate.
eviation, respectively.
AADs was  added to Model B, the effect of proteinuria was no longer
independent, while that of eGFR remained independent (Table 2,
Model C). Furthermore, when the echocardiographic parameters
including LVEF and LAD were added to Model B, both the effects of
eGFR and proteinuria were no longer independent (Table 2, Model
D).
Discussion
In the present study, we found that the percentage of patients
with persistent AF increased in accordance with both the decline
in eGFR and the presence of proteinuria, and these associations
remained independent even when adjusted by the various patient
backgrounds. The associations were diminished when adjusted by
echocardiographic parameters including LVEF and LAD, indicating
that the effects of the kidney-related markers seem to be essentially
representing these parameters.
Several large-scale cohort studies including both of cross-
sectional [5,6] and prospective design [7–10] have demonstrated
the epidemiological linking between renal dysfunction and AF, and
also that between proteinuria and AF [6,10].  As to the natural time
course, AF progresses from short, rare episodes, to longer and more
frequent attacks, and ﬁnally many patients will develop sustained
forms of AF over time [36]. Through this natural time course of AF
progression, atrial ﬁbrosis may  contribute to the onset of AF [37]
and also be thought to contribute to its perpetuation [22]. There-
fore, considering the coherent pathogenesis through the course of
AF progression, it might be natural to hypothesize that, if renal dys-
function and the presence of proteinuria are associated with the
incidence of AF, they would also be associated with AF perpetua-
tion via the similar pathogenesis, and consequently they are more
linked to the persistent form of AF than the paroxysmal one.
Although several studies have addressed the time course and
the risk factors for AF progression [2,38],  they failed to address the
effect of kidney-related markers. Accordingly, to the best of our
knowledge, the present study appears to be the ﬁrst to provide
the simple epidemiological evidence regarding the association
56 S. Suzuki et al. / Journal of Card
Table  2
Relation of estimated glomerular ﬁltration rate and proteinuria to prevalence rate
of persistent form of atrial ﬁbrillation: Shinken Database 2004–2010, Tokyo, Japan.
Odds ratio 95% CI p-Value
(A) Non-adjusted model
Estimated GFR (category)
T1 (reference)
T2 1.49 1.16–1.91 0.002
T3  2.23 1.74–2.85 <0.001
Estimated GFR (numerous) 0.98 0.97–0.99 <0.001
Proteinuria 1.73 1.17–2.56 0.005
(B)  Adjusted by patient backgrounds
Model 1
Estimated GFR (category)
T1 (reference)
T2 1.48 1.11–2.06 0.007
T3 2.11 1.54–2.88 <0.001
Proteinuria 1.59 1.06–2.38 0.023
Model 2
Estimated GFR (numerous) 0.98 0.97–0.99 <0.001
Proteinuria 1.51 1.03–2.22 0.035
(C)  Adjusted by (B) + antiarrhythmic drugs
Model 1
Estimated GFR (category)
T1 (reference)
T2 1.71 1.22–2.41 0.002
T3 2.15 1.52–3.04 <0.001
Proteinuria 1.24 0.79–1.94 0.340
Model 2
Estimated GFR (numerous) 0.98 0.97–0.99 <0.001
Proteinuria 1.23 0.78–1.95 0.368
(D)  Adjusted by (B) + Echocardiographic parameters
Model 1
Estimated GFR (category)
T1 (reference)
T2 1.32 0.91–1.90 0.134
T3  1.42 0.95–2.12 0.082
Proteinuria 0.91 0.56–1.49 0.718
Model 2
Estimated GFR (numerous) 0.99 0.98–1.00 0.425
Proteinuria 0.90 0.55–1.48 0.697
CI, conﬁdence interval; GFR, glomerular ﬁltration rate.
In  the model (B), the effects of estimated GFR and proteinuria were adjusted by
patient backgrounds which were signiﬁcantly different between paroxysmal and
persistent AF: age, congestive heart failure, organic cardiac disease, valvular heart
disease, cardiomyopathy, diabetes mellitus, dyslipidemia and history of cerebral
infarction or transient ischemic attack.
In the Model (C), the model was adjusted by the covariates in Model (B), and the
antiarrhythmic drug which were signiﬁcantly different between paroxysmal and
persistent AF: antiarrhythmic drug class 1 and 4, and digitalis.
In  the Model (D), the model was  adjusted by the covariates in the Model (B), and the
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Study). Am J Cardiol 2009;104:1551–5.chocardiographic parameters, including left ventricular ejection fraction and left
trial diameter.
etween kidney-related markers and the presence of AF pro-
ression, although the analysis was limited to the cross-sectional
esign.
The effect of worsening of kidney-related markers on AF per-
etuation may  be understood by the similar pathogenesis with the
ffect of CKD on AF development. Subjects with renal dysfunc-
ion are more likely to develop hypertension [39]. The overload
f the extracellular ﬂuid might lead to left ventricular hyper-
rophy and poor ventricular compliance, which would possibly
e the cause of atrial stretch and ﬁbrosis, well-known patho-
enesis of AF [19,40]. In addition, CKD might promote atrial
brosis and electric remodeling [41], through the activation of the
enin–angiotensin–aldosterone system [42], thus creating the basis
or AF development [43]. Also indirectly, CKD might promote AF
hrough an increased risk of cardiovascular disease, including heart
ailure and ischemic heart disease [19,44],  or through sympathetic
veractivity [45]. However, in the present study, the pathogene-
is appeared to be more essentially represented by the decline of
VEF and the increase in LAD, because the relationships of eGFRiology 61 (2013) 53–57
or proteinuria with persistent form of AF were completely dimin-
ished when adjusted by these echocardiographic parameters. This
ﬁnding suggests that the parameters of echocardiography, includ-
ing LAD and LVEF, could more directly indicate the stretch and the
remodeling of left atrium than kidney-related markers [2].
As several studies have addressed, decline of renal function is
associated with the failure of therapeutic intervention for parox-
ysmal AF [24,46–48].  Therefore, the effects of the kidney-related
markers could be, at least in part, the representing markers for
such failure of therapeutic intervention. Actually, in the present
study, the association between proteinuria and persistent form of
AF was  abolished when adjusted by the use of AADs. However, in
the model, the effect of eGFR remained independent, indicating
such confounding relationship appeared to have an only limited
importance in the present study.
The present study with a cross-sectional design has an inher-
ent limitation. Because of the cross-sectional manner, the present
results could not distinguish whether kidney damage is a cause
or a result of AF perpetuation. A recent study demonstrated that
renal function could be improved after pulmonary vein isola-
tion is performed [49], suggesting AF itself could be the cause of
renal dysfunction, which supports the concept of the bidirectional
relationship between renal dysfunction and AF development [8].
Therefore, the effect of renal dysfunction and the presence of pro-
teinuria on AF perpetuation should be ascertained in a prospective
study in future.
Conclusions
The present cross-sectional study demonstrated that the decline
in renal function and the presence of proteinuria are linked to the
persistent form of AF in patients, but their role in the pathogen-
esis does not seem to exceed the cardiac remodeling and stretch,
represented by LAD and LVEF. The pathological linking should be
ascertained in a prospective study in future.
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